Latest Presentations XP-8121 Program Overview Presentation View Presentation 740.2 KB August 2026 Corporate Presentation View Presentation 1 MB Events There are no events scheduled at this time. View All Events News Releases 02 Oct 2026 Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 09 Sep 2026 Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism View All News Latest Quarterly Earnings Show all Q2 2026 Webcast Q2 2026 Press Release Q2 2026 Form 10-Q Featured Reports Mar 02, 2026 2025 Annual Report 17.4 MB Mar 06, 2025 2024 Annual Report 16.6 MB View All Reports
09 Sep 2026 Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
